AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02689843
Drug: Cyproterone compound + Spironolactone
RxNorm normalized name: cyproterone
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone compound (Cyproterone Acetate 2mg-Ethinyl estradiol 35mcg) 1 tablet daily + Spironolactone 50 mg twice daily
Trial: NCT03173417
Drug: fludarabine and cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days
Trial: NCT03322293
Drug: Aminolevulinic Acid Topical 20% Topical Solution
RxNorm normalized name: aminolevulinic acid topical 20% topical solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDT involves the topical application of aminolevulinic acid (ALA), or one of its derivatives, as a photosensitizing agent. Subjects will receive ALA in all treatment arms (A, B, and C).
Trial: NCT02659943
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
Trial: NCT05715385
Drug: eye drop bromfenac 0.09%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily e/d bromfenac 0.09% for 6 weeks
Trial: NCT05715385
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation group. No intervention done. Only eye drop carboxymethyl cellulose 0.5% to be instilled thrice a day for 6 weeks.
Trial: NCT03583567
Drug: 0.9% Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will receive normal saline as placebo.
Trial: NCT00942305
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received their first dose of study drug within 30 (+5) days post-transplant and were treated through Week 13 post-transplant.~Matching placebo administered for each cohort.
Trial: NCT02342470
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug : Placebo
Trial: NCT02342470
Drug: PMK-S005 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug : PMK-S005 1 (50mg)
Trial: NCT02342470
Drug: PMK-S005 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug : PMK-S005 2 (100mg)
Trial: NCT02342470
Drug: PMK-S005 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug : PMK-S005 3 (150mg)
Trial: NCT04144101
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 60 mg QD Oral
Trial: NCT03441113
Drug: MMB
RxNorm normalized name: Methylmethionine sulfonium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered orally once daily
Trial: NCT01449721
Drug: Intravenous fluid
RxNorm normalized name: Intravenous fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Sodium chloride intravenous fluid
Trial: NCT01260857
Drug: Aldazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldazide 25 mg OD
Trial: NCT00334672
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00334672
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00334672
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05635942
Drug: optimized quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association of amoxicillin 3 g/day + Esomeprazole, nitroimidazole and clarithromycin for 14 days
Trial: NCT05635942
Drug: standard quadruple therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association of amoxicillin 2 g/day + Esomeprazole, nitroimidazole and clarithromycin for 14 days
Trial: NCT01464840
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg intravenous infused over 1 hour
Trial: NCT03212716
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of diltiazem
Trial: NCT02617615
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It will be identical in appearance and similar in weight to the MB-110 hard-gel capsule.
Trial: NCT03415516
Drug: Single Bond2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adhesive systems
Trial: NCT01723072
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to omalizumab
Trial: NCT02782312
Drug: ICS+LABA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seretide is inhaled for one year
Trial: NCT02652169
Drug: PRF mixed with amikacin and teicoplanin
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRF, mixed with amikacin and teicoplanin is applied to the chronic ulcer
Trial: NCT02652169
Drug: PRF mixed with PHMB plus Macrogolol
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRF, mixed with Lavasorb is applied to the chronic ulcer
Trial: NCT00457652
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7 day treatment rosuvastatin 20mg
Trial: NCT05410678
Drug: Renal stent
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: renal stent implantation in ectatic/aneurysmatic coronary arteries
Trial: NCT01805895
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This arm will receive a total of 5 doses of minocycline. Dose 1 will be 400mg IV within 12-hours of onset of symptoms. Dose 2 will be 400mg oral, given daily on days 2-5 . Each dose is 24 hours apart.
Trial: NCT03490903
Drug: Fentanyl Injection
RxNorm normalized name: fentanyl Injection
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl is commonly administered to treat pain during invasive procedures such as coronary angiography. Intravenous fentanyl injection dosages are determined by the physician operator, and administered by the circulating nurse.
Trial: NCT04197739
Drug: Amikacin
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in the intervention arm will receive a fixed, single daily dose of amikacin, 500 mg, a day.~Patients in the Comparator arm will receive a weight adjusted loading dose of amikacin (15 mg/kg adjusted body weight) and continue in adjusted intervals according to the Barnes Jewish Hospital nomogram
Trial: NCT00004242
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00597818
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules for oral administration
Trial: NCT00597818
Drug: Non-steroidal anti-inflammatory drug
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any marketed non-steroidal anti-inflammatory drug used by the participants as standard care.
Trial: NCT02751268
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral infraorbital and infratrochlear nerve block before general anesthesia with normal saline
Trial: NCT03090139
Drug: Anti-TNF Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF therapy.
Trial: NCT00440440
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel to be applied daily, starting does 5g.
Trial: NCT00440440
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo gel apply daily
Trial: NCT00329173
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02910050
Drug: Aromatase Inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants will receive any kind of aromatase inhibitor which has not been received before (steroidal AI change to nonsteroidal AI and vice versa), Letrozole 2.5mg once a day orally, Anastrozole 1mg once a day orally, Exemestane 25mg once a day orally
Trial: NCT02943239
Drug: REGN2477
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REGN2477
Trial: NCT03764527
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses a day for 3 days, under supervision
Trial: NCT00939159
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg capsules by mouth 3 times a week for 3 weeks in a 28-day cycle.
Trial: NCT02184364
Drug: Low dose of Klimadynon®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02184364
Drug: High dose of Klimadynon®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02184364
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00662818
Drug: Acetaminophen/Paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen/Paracetamol (500 mg X 2 dosage units)
Trial: NCT00662818
Drug: Placebo to Acetaminophen/Paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to acetaminophen/paracetamol (500 mg X 2 dosage units)
Trial: NCT04647552
Drug: Drug Steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrocortisone injection
Trial: NCT00659178
Drug: SB-485232 (interleukin 18), pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-485232 (interleukin 18), pegylated liposomal doxorubicin
Trial: NCT00388791
Drug: Systane Free
RxNorm normalized name: Systane Free
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02974868
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01755507
Drug: norUDCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of different dosages of norUDCA acid administered orally.
Trial: NCT01755507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03286101
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention is composed of a single application of the vehicle control.
Trial: NCT00672945
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02389959
Drug: Placebo (Saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4mL of saline will be mixed by the Stanford Hospital Pharmacy as a control
Trial: NCT02751320
Drug: 1150ppm F
RxNorm normalized name: F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
Trial: NCT03901482
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for STS101
Trial: NCT01382277
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 20 mg per day for 76 weeks
Trial: NCT00258557
Drug: LPV/RTV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks
Trial: NCT03148444
Drug: cefalexin 500 mg qid or roxithromycin 150 mg bid
RxNorm normalized name: roxithromycin 150 MG
DrugBank: Roxithromycin (DB00778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibiotics treatment for five days following implantation of cardiac device
Trial: NCT02794922
Drug: Neurovit Forte
RxNorm normalized name: Erythroped Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00409539
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 2 week duration.
Trial: NCT02204501
Drug: Vapendavir 264 mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twelve subjects (6 male and 6 female) will receive 264 mg vapendavir (achieved with two 132 mg vapendavir capsules) BID daily as divided dose given in the morning and evening 12 hours apart for seven days.
Trial: NCT02204501
Drug: Vapendavir 528 mg QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twelve subjects (6 male and 6 female) will receive 528 mg vapendavir (achieved with four 132 mg vapendavir capsules) QD in the morning for seven days
Trial: NCT00409539
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken for the 8 week duration, in parallel with alternative arms (doses of 20, 40, 80 or 120mg SMP-986).
Trial: NCT00531453
Drug: bortezomib, dexamethasone, thalidomide, and cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VELCADE (bortezomib) twice weekly for 4 cycles (4 doses per cycle), prior to high-dose chemotherapy(HDT)and stem cell transplantation(SCT). Subjects will receive VELCADE 1.3 mg/m2 as an intravenous (i.v.) bolus injection on Days 1,4,8, and 11, followed by a 10 day rest period (Days 12 to 21).~Dexamethasone 40 mg/day will be given by mouth (p.o.) on Days 1-4 and Days 9-12 in each of 4 cycles.~Thalidomide will be given by mouth (p.o.) every day, starting on Day 1 of Cycle 1 (e.g., the same day of the first dose of VELCADE) and continuing until Day 21 of Cycle 4 at a dose of 100 mg/day (bedtime).~Cyclophosphamide will be given as an intravenous (i.v.) dose of 400 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for a total of 4 cycles.
Trial: NCT00305162
Drug: Placebo bolus & placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo bolus (30 mcg/kg) \& placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
Trial: NCT00305162
Drug: Placebo capsules - end of infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
Trial: NCT00003509
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Stage IV Melanoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT04447820
Drug: K-877-ER (Dose A)
RxNorm normalized name: K+ 8 MEQ Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose A Oral Administration
Trial: NCT04447820
Drug: K-877-ER (Dose B)
RxNorm normalized name: K+ 8 MEQ Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose B Oral Administration
Trial: NCT04447820
Drug: K-877-IR
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-877-IR Oral Administration
Trial: NCT00305162
Drug: Placebo capsules - as soon as possible after randomization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules given as soon as possible after randomization to mimic 600mg clopidogrel dosing
Trial: NCT02400801
Drug: ethinylestradiol + dienogest
RxNorm normalized name: Dienogest
DrugBank: Dienogest (DB09123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral oestroprogestogen
Trial: NCT02019667
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00621790
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01270074
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azithromycin will be given as a liquid preparation at a dose of 10 mg/kg three times per week from three months of age until three years of age
Trial: NCT02101385
Drug: Genomically Directed Monotherapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to Experimental Arm A will receive an FDA approved drug at standard dose for four cycles (12-16 weeks total duration, depending on cycle length). The CGTB will assign therapy to each participant individually based on biomarkers/pathways identified by DNA sequencing:
Trial: NCT00157339
Drug: Human Insulin Inhalation Powder
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient specific dose, inhaled, before meals, 12 months
Trial: NCT01746862
Drug: Saizen®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the Saizen test group will receive Saizen (recombinant-human growth hormone \[r-hGH\]) subcutaneously 6 days per week at a weight based dose of 0.067 milligram per kilogram of body weight per day (mg/kg/day) for 12 months.
Trial: NCT01746862
Drug: Saizen®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the Saizen control group will receive no treatment for the first 6 months and thereafter will receive Saizen (r-hGH) subcutaneously 6 days per week at a weight based dose of 0.067 mg/kg/day for the next 6 months.
Trial: NCT06729658
Drug: Madopar
RxNorm normalized name: Madopar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group participants will receive Madopar 125mg for 6 days.
Trial: NCT06729658
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group participants will receive placebo for 6 days.
Trial: NCT00427310
Drug: sodium heparin
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04666623
Drug: placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: unlabeled nasal injectors, each device will deliver 28mg of placebo in a 200 μL solution, so in order to achieve the 56mg dose two devices will be required. On each dosing day during the trial, participants will self-administer at 2 time points 1 spray of the nasal spray into each nostril. Each administration will be separated by 5 minutes. The participants will receive the intervention twice weekly for 4 consecutive weeks.
Trial: NCT01964027
Drug: second line chemoregime for advanced gastric cancer
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan(Camptosar)150mg /m2 d1,（intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment \* 6 cycles as the second line chemoregime for advanced gastric cancer
Trial: NCT02253394
Drug: Ambrisentan plus Spironolactone
RxNorm normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cardiopulmonary fitness
Trial: NCT02070939
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive single doses of PF-06260414 matching placebo (solution) in a dose escalation format
Trial: NCT02070939
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive PF-06260414 matching placebo doses (solution) of 3, 10, 30, 100mg BID and 60 mg QD for 14 days
Trial: NCT02070939
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Japanese subjects may receive PF-06260414 matching placebo doses (solution) twice daily for 14 days
Trial: NCT02314780
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02413853
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02413853
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02115984
Drug: Panagen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02115984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04390646
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug administered by a subcutaneous pump
Trial: NCT00225017
Drug: current antiretroviral regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue current antiretroviral regimen for 24 weeks, single or RTV-boosted PI plus \> 2 NRTIs
Trial: NCT01231009
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Dexamethasone, 8mg three times per day tapering down for 7 days Per os dexamethasone, 2mg per day tapering down for 7 days
Trial: NCT01909804
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg tablet administered orally once daily
Trial: NCT05558397
Drug: Control Group (Oral morphine)
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of morphine, pregabalin or duloxetin
Trial: NCT04394208
Drug: Silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin Oral at a dose of 420 mg/day in 3 divided doses.
Trial: NCT04394208
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT03257943
Drug: SKLICE (ivermectin) Lotion, 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKLICE (ivermectin) Lotion, 0.5% (Arbor Pharmaceuticals, LLC)
Trial: NCT03257943
Drug: Vehicle of the Test product
RxNorm normalized name: The Magic Bullet Rectal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle for Ivermectin Lotion, 0.5% (Taro Pharmaceuticals Inc.)